Doxycycline: Difference between revisions
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
*200 mg/day PO q12-24h x 5-7 days | *200 mg/day PO q12-24h x 5-7 days | ||
===Chlamydia=== | ===[[Chlamydia]]=== | ||
*100 mg PO q12h x 7 days | *100 mg PO q12h x 7 days | ||
* | *Also prophylaxis for sexual assault victims | ||
===Gonorrhea=== | ===[[Gonorrhea]]=== | ||
*100 mg PO q12h x 7 days | *100 mg PO q12h x 7 days | ||
*Not first line- use with [[ceftriaxone]] | *Not first line- use with [[ceftriaxone]] | ||
===PID=== | ===[[PID]]=== | ||
*Outpatient | *Outpatient | ||
**100 mg PO q12h x 14 days | **100 mg PO q12h x 14 days | ||
| Line 37: | Line 37: | ||
*100 mg PO q12h x 7 days | *100 mg PO q12h x 7 days | ||
===Syphilis=== | ===[[Syphilis]]=== | ||
If hypersensitivity to Penicillin | If hypersensitivity to Penicillin | ||
====Primary/Secondary/Latent<1 year==== | ====Primary/Secondary/Latent<1 year==== | ||
| Line 50: | Line 50: | ||
*100 mg PO q12h x 7 days | *100 mg PO q12h x 7 days | ||
===Epididymitis=== | ===[[Epididymitis]]=== | ||
*100 mg PO q12h x 10 days | *100 mg PO q12h x 10 days | ||
===Proctitis=== | ===[[Proctitis]]=== | ||
*100 mg PO q12h x 7 days | *100 mg PO q12h x 7 days | ||
===Lyme Disease=== | ===[[Lyme Disease]]=== | ||
*100 mg PO q12h x14-21 days | *100 mg PO q12h x14-21 days | ||
*Treat for 28 days if Lyme arthritis | *Treat for 28 days if Lyme arthritis | ||
===Anthrax=== | ===[[Anthrax]]=== | ||
First line agent in pregnancy | First line agent in pregnancy | ||
====Inhalational, GI, Oropharyngeal==== | ====Inhalational, GI, Oropharyngeal==== | ||
| Line 70: | Line 70: | ||
*100 mg PO qd x 60 days or until anthrax exposure excluded | *100 mg PO qd x 60 days or until anthrax exposure excluded | ||
===Malaria prophylaxis=== | ===[[Malaria]] prophylaxis=== | ||
*100 mg PO qd | *100 mg PO qd | ||
**Start 1-2 days prior to exposure | **Start 1-2 days prior to exposure | ||
| Line 76: | Line 76: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===General Infections=== | |||
*>8 years old | |||
*2.2 mg/kg PO/IV qd | |||
**Start: 2.2 mg/kg PO/IV q12h x 1 day | |||
**Max 100 mg/kg/dose | |||
**Frequency for severe infections is q12h | |||
===Severe Acne Vulgaris=== | |||
*>8 years old | |||
*2.2 mg/kg PO/IV qd | |||
**Start: 2.2 mg/kg PO/IV q12h x 1 day | |||
**Max 100 mg/kg/dose | |||
===Atypical CAP=== | |||
*>8 years old | |||
*2-4 mg/kg/day PO divided q12h x7-10 days | |||
===[[Chlamydia]]=== | |||
*>8 years old | |||
*100 mg PO q12h x 7 days | |||
*Also prophylaxis for sexual assault victims | |||
===[[Gonorrhea]]=== | |||
*>8 years old/>45 kg | |||
*100 mg PO q12h x 7 days | |||
*Not first line- use with [[ceftriaxone]] | |||
===[[PID]]=== | |||
*Same as adult dosing | |||
===Cervicitis=== | |||
*Adolescents | |||
*100 mg PO q12h x 7 days | |||
===Lymphogranuloma Venereum=== | |||
*Adolescents | |||
*100 mg PO q12h x 21 days | |||
===Urethritis=== | |||
*Adolescents | |||
*100 mg PO q12h x 7 days | |||
===[[Epididymitis]]=== | |||
*Adolescents | |||
*100 mg PO q12h x 10 days | |||
===[[Proctitis]]=== | |||
*Adolescents | |||
*100 mg PO q12h x 7 days | |||
===[[Lyme Disease]]=== | |||
*>8 years old | |||
*100 mg PO q12h x14-21 days | |||
*Treat for 28 days if Lyme arthritis | |||
===[[Anthrax]]=== | |||
First line agent in pregnancy | |||
====Inhalational, GI, Oropharyngeal==== | |||
*2.2 mg/kg PO q12h x 60 days | |||
====Cutaneous==== | |||
*2.2 mg/kg PO q12h x 7-10 days | |||
*Max 100 mg/dose | |||
*60 day regimen if bioterrorism suspected | |||
====Post exposure prophylaxis==== | |||
*2.2 mg/kg PO qd x 60 days or until anthrax exposure excluded | |||
*Max 100 mg/dose | |||
===[[Malaria]] prophylaxis=== | |||
*> 8 years old | |||
*2.2 mg/kg PO qd | |||
**Start 1-2 days prior to exposure | |||
**Continue 4 weeks after exposure | |||
**Max 100 mg/dose | |||
==Special Populations== | ==Special Populations== | ||
*Pregnancy: | *Pregnancy: D | ||
*Lactation: | *Lactation: Possibly Unsafe; consider alternatives | ||
*Renal Dosing | *Renal Dosing Adult and Pediatric | ||
**No adjustment | |||
** | *Hepatic Dosing Adult and Pediatric | ||
*Hepatic Dosing | **Not defined | ||
** | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Pregnancy | |||
*Age <8 years | |||
*Caution: | |||
**Lupus | |||
**Child bearing potential | |||
**Hepatic impairment | |||
**Candidiasis | |||
**Recent colitis due to abx | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Tooth discoloration children <8 years old | |||
*Photosensitivity | |||
*C. Diff diarrhea | |||
*Hypersensitivity reaction | |||
*Skin reaction | |||
*Vasculitis | |||
*Pericarditis | |||
*Autoimmune hepatitis | |||
*Hepatotoxicity | |||
*Nephrotoxicity | |||
*Esophagitis/ulcer | |||
*[[Pancreatitis]] | |||
*[[Thrombocytopenia]] | |||
*[[Neutropenia]] | |||
*Hemolytic anemia | |||
*[[Pseudotumor cerebri]] | |||
*Bulging fontanelles | |||
*Jarisch-Herxheimer reaction | |||
*Fetal harm | |||
===Common=== | ===Common=== | ||
*Headache | |||
*Nausea | |||
*Dyspepsia | |||
*Arthralgia | |||
*Diarrhea | |||
*Rash | |||
*Dysmenorrhea | |||
*Photosensitivity | |||
*Vulvovaginal candidiasis | |||
*Skin discoloration | |||
*Elevated BUN | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 18 hours | ||
*Metabolism: | *Metabolism: Unknown and minimal liver/CYP450 | ||
*Excretion: | *Excretion: Feces and urine | ||
*Mechanism of Action: | *Mechanism of Action: Bacteriostatic | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
| Line 226: | Line 335: | ||
==Source== | ==Source== | ||
*Epocrates | |||
<references/> | <references/> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 05:24, 15 April 2015
General
- Type: Tetracyclines
- Dosage Forms: PO and IV (20 mg, 50 mg, 75 mg, 100 mg, 150 mg, 25mg/5 mL)
- Common Trade Names: Adoxa, Avidoxy, Doryx, Monodox, Oracea, Periostat, Vibramycin
Adult Dosing
General Infections
- 100 mg PO/IV qd or q12h depending on severity
- Variable duration
Severe Acne Vulgaris
- 100 mg PO qd
- Start 100 mg PO q12h x 1 day
Periodontitis
- 20 mg PO q12h
Acute Bacterial Sinusitis
- 200 mg/day PO q12-24h x 5-7 days
Chlamydia
- 100 mg PO q12h x 7 days
- Also prophylaxis for sexual assault victims
Gonorrhea
- 100 mg PO q12h x 7 days
- Not first line- use with ceftriaxone
PID
- Outpatient
- 100 mg PO q12h x 14 days
- Inpatient
- 100 mg IV q12h x 14 days
- Switch to PO when able and complete course
Cervicitis
- 100 mg PO q12h x 7 days
Syphilis
If hypersensitivity to Penicillin
Primary/Secondary/Latent<1 year
- 100 mg PO q12h x 14 days
Latent >1 year/unknown
- 100 mg PO q12h x 28 days
Lymphogranuloma Venereum
- 100 mg PO q12h x 21 days
Urethritis
- 100 mg PO q12h x 7 days
Epididymitis
- 100 mg PO q12h x 10 days
Proctitis
- 100 mg PO q12h x 7 days
Lyme Disease
- 100 mg PO q12h x14-21 days
- Treat for 28 days if Lyme arthritis
Anthrax
First line agent in pregnancy
Inhalational, GI, Oropharyngeal
- 100 mg PO q12h x 60 days
Cutaneous
- 100 mg PO q12h x 7-10 days
- 60 day regimen if bioterrorism suspected
Post exposure prophylaxis
- 100 mg PO qd x 60 days or until anthrax exposure excluded
Malaria prophylaxis
- 100 mg PO qd
- Start 1-2 days prior to exposure
- Continue 4 weeks after exposure
Pediatric Dosing
General Infections
- >8 years old
- 2.2 mg/kg PO/IV qd
- Start: 2.2 mg/kg PO/IV q12h x 1 day
- Max 100 mg/kg/dose
- Frequency for severe infections is q12h
Severe Acne Vulgaris
- >8 years old
- 2.2 mg/kg PO/IV qd
- Start: 2.2 mg/kg PO/IV q12h x 1 day
- Max 100 mg/kg/dose
Atypical CAP
- >8 years old
- 2-4 mg/kg/day PO divided q12h x7-10 days
Chlamydia
- >8 years old
- 100 mg PO q12h x 7 days
- Also prophylaxis for sexual assault victims
Gonorrhea
- >8 years old/>45 kg
- 100 mg PO q12h x 7 days
- Not first line- use with ceftriaxone
PID
- Same as adult dosing
Cervicitis
- Adolescents
- 100 mg PO q12h x 7 days
Lymphogranuloma Venereum
- Adolescents
- 100 mg PO q12h x 21 days
Urethritis
- Adolescents
- 100 mg PO q12h x 7 days
Epididymitis
- Adolescents
- 100 mg PO q12h x 10 days
Proctitis
- Adolescents
- 100 mg PO q12h x 7 days
Lyme Disease
- >8 years old
- 100 mg PO q12h x14-21 days
- Treat for 28 days if Lyme arthritis
Anthrax
First line agent in pregnancy
Inhalational, GI, Oropharyngeal
- 2.2 mg/kg PO q12h x 60 days
Cutaneous
- 2.2 mg/kg PO q12h x 7-10 days
- Max 100 mg/dose
- 60 day regimen if bioterrorism suspected
Post exposure prophylaxis
- 2.2 mg/kg PO qd x 60 days or until anthrax exposure excluded
- Max 100 mg/dose
Malaria prophylaxis
- > 8 years old
- 2.2 mg/kg PO qd
- Start 1-2 days prior to exposure
- Continue 4 weeks after exposure
- Max 100 mg/dose
Special Populations
- Pregnancy: D
- Lactation: Possibly Unsafe; consider alternatives
- Renal Dosing Adult and Pediatric
- No adjustment
- Hepatic Dosing Adult and Pediatric
- Not defined
Contraindications
- Allergy to class/drug
- Pregnancy
- Age <8 years
- Caution:
- Lupus
- Child bearing potential
- Hepatic impairment
- Candidiasis
- Recent colitis due to abx
Adverse Reactions
Serious
- Tooth discoloration children <8 years old
- Photosensitivity
- C. Diff diarrhea
- Hypersensitivity reaction
- Skin reaction
- Vasculitis
- Pericarditis
- Autoimmune hepatitis
- Hepatotoxicity
- Nephrotoxicity
- Esophagitis/ulcer
- Pancreatitis
- Thrombocytopenia
- Neutropenia
- Hemolytic anemia
- Pseudotumor cerebri
- Bulging fontanelles
- Jarisch-Herxheimer reaction
- Fetal harm
Common
- Headache
- Nausea
- Dyspepsia
- Arthralgia
- Diarrhea
- Rash
- Dysmenorrhea
- Photosensitivity
- Vulvovaginal candidiasis
- Skin discoloration
- Elevated BUN
Pharmacology
- Half-life: 18 hours
- Metabolism: Unknown and minimal liver/CYP450
- Excretion: Feces and urine
- Mechanism of Action: Bacteriostatic
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
Source
- Epocrates
- ↑ Sanford Guide to Antimicrobial Therapy 2014
